As the first oncogenic translocation identified in B-cell lymphomas, several transgenic mouse models have been generated over the years to drive MYC overexpression throughout B-cell development under the control of different IG enhancers, in an attempt to mimic the IGH-MYC translocation (74–77). This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.